Advertisement

Topics

Latest "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy" News Stories

05:43 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy" found in our extensive news archives from over 250 global news sources.

More Information about Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy for you to read. Along with our medical data and news we also list Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy Clinical Trials, which are updated daily. BioPortfolio also has a large database of Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy Companies for you to search.

Showing "Efficacy Trial Comparing ZD6474 With Erlotinib NSCLC After" News Articles 1–25 of 11,000+

Tuesday 19th March 2019

Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.

SUZHOU, China, March 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase I clinical trial of anti-cluster of differentiation 47 (anti-CD47) monoclonal antibody drug candidate (IBI188) in the ...


FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer

F. Hoffmann-La Roche Ltd / FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the ...

Come Visit Visikol at AACR in Atlanta at Booth #3252

This year the American Association for Cancer Research annual meeting will be held at the Georgia World Congress Center in Atlanta, Georgia, from March 29 to April 3, 2019, with exhibit dates March 31 to April 3. WHITEHOUSE, N.J. (PRWEB) March 19, 2019 The AACR annual conference pulls together a diverse group of clinical and laboratory researchers and is a great opportunity to see the most cuttin...


Xynomic Extends Phase III Abexinostat Trial to China and Europe

Xynomic, a US-Shanghai oncology pharma, announced that China, Spain and Poland authorities have approved Phase III trials of Xynomic's abexinostat, in combination with pazopanib, in patients with renal cell carcinoma (RCC). Abexinostat is a novel HDAC inhibitor. Xynomic has already started the same trial in the US and South Korea. Xynomic in-licensed the drug in 2017 (see story), but did not discl...

Monday 18th March 2019

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

[Articles] Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial

Deferoxamine mesylate was safe. However, the primary result showed that further study of the efficacy of deferoxamine mesylate with anticipation that the drug would significantly improve the chance of good clinical outcome (ie, mRS score of 0–2) at day 90 would be futile.

[Comment] Reduction of iron neurotoxicity in intracerebral haemorrhage

The chances of recovering from acute spontaneous intracerebral haemorrhage, the most serious form of acute stroke, depend on the location, extent, and degree of bleeding.1 However, a substantial amount of data from animal studies also suggests that prognosis is related to the toxic effects of iron and other haemoglobin breakdown products from the immuno–inflammatory response, which manifest clin...

FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer

– Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) – – First new initial treatment option approved by the U.S. Food and Drug Administration (FDA) for people with ES-SCLC in more than 20 years – ...

STAT Plus: A small #California #biotech firm announced clinical trial results for a new drug called lebrikizumab that alleviated the signs and symptoms of serious eczema far greater than a placebo. https://buff.ly/2HG5gX5 

STAT Plus: A small #California #biotech firm announced clinical trial results for a new drug called lebrikizumab that alleviated the signs and symptoms of serious eczema far greater than a placebo. https://buff.ly/2HG5gX5 

Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis

 Press Release Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis ................................................ Trial to randomize 30 blepharitis patients in clinical sites across the U.S. Top-line results expected in Q4 2019 Targets the estimated $500+ million U.S. blepharitis market ................................................March 19, 2019 - release at 7:30 ...

Atezolizumab Shows Comparable Real-World Tolerability, Efficacy in Urothelial Carcinoma

Atezolizumab (Tecentriq) demonstrated consistent safety and efficacy with prior studies of the PD-L1 inhibitor in patients with locally advanced or metastatic urothelial carcinoma, including clinically relevant subgroups reflective of real-world clinical practice.

Brenton Tarrant could avoid terror charges as murder could be easier to prove, legal experts say – Daily Mail

Brenton Tarrant could avoid terror charges as murder could be easier to prove, legal experts say Daily MailAccused Christchurch mosque shooter Brenton Tarrant could avoid terror charges amid fears the trial will allow him to 'espouse' his ideological views.

A fertility tracking app, Dot, is billing itself as contraception — and touting the results of a new efficacy study. But there’s also significant debate over how to measure the effectiveness of these tools. https://buff.ly/2CpdQpO 

A fertility tracking app, Dot, is billing itself as contraception — and touting the results of a new efficacy study. But there’s also significant debate over how to measure the effectiveness of these tools. https://buff.ly/2CpdQpO 

Telix Pharmaceuticals Limited (TLX-AU): Updated PCa imaging guidelines de-risk lead asset

goetzpartners securities Limited 18-March-2019 / 20:05 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail cli...

A fertility app bills itself as contraception, raising questions about marketing and efficacy

A fertility tracking app, Dot, is billing itself as contraception — and touting the results of a new efficacy study. But there’s also significant debate over how to measure the…

New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Approved for Australian Women(1)

NERLYNX® (neratinib) now approved by the Therapeutic Goods Administration for Australian women2 Leading Australian breast cancer oncologist says this is a 'huge step forward' for Australian women Five-year data shows NERLYNX reduces the risk of invasive disease recurrence or death by 42% in women with early-stage, HER2+/HR+ breast cancer3 NERLYNX now available to eligible women at ...

Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will host a conference call and live webcast to discuss topline results from the EMPOWUR international pivotal phase 3 study on Tuesday, March 19, 2019 at 8:30 a.m. ET. A ques...

AZ’ Farxiga shows CV benefit in diabetes patients

New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting

Oral Plenary Presentation Receives SGO Presidential Award Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology...

Cold Genesys studies NMIBC candidate in combo with Merck's Keytruda

Cold Genesys Inc. entered a trial collaboration with Merck & Co. Inc. to study Merck’s Keytruda (pembrolizumab) in combinat...

Cold Genesys secures $22M Series C round for oncolytic virus in bladder cancer

The company’s lead product candidate, CG0070, has completed a Phase II study and will be tested in another trial, combined with Merck&#

Real-Time Computer-Aided Detection During Colonoscopy

A randomized, controlled trial shows increased adenoma detection with CADe, but the devil is in the details.

Measles Hearings Offer Counterpoint To Pricing Spotlight: Vaccines Touted As Cost-Effective Solution To Outbreaks

Congressional hearings on the recent outbreaks of measles and other vaccine-preventable diseases offered a positive theme for the industry during...   

Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase

The agency requested a funding increase in part to implement 2018 legislation intended to combat the opioid crisis, but also...    

Setback for Allergy’s birch pollen immunotherapy

Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks